1Buzello M, Tornig J, Faulhaber J, et al.The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia.J Am Soc Nephrol,2003,14:311-316.
2Mann JF, Gerstein HC, Dulau-Florea I,et al.Cardiovascular risk in patients with mild renal insufficiency.Kidney Int Suppl,2003,(84):S192-S196.
3Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.J Am Soc Nephrol,2003,14:1927-1939.
4Drueke T, Witko-Sarsat V, Massy Z,et al.Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.Circulation,2002,106:2212-2217.
5Pecoits-Filho R, Stenvinkel P, Marchlewska A,et al.A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.Kidney Int Suppl,2003,(84):S172-S176.
6Boaz M, Smetana S, Weinstein T,et al.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.Lancet,2000,356:1213-1218.
7Tepel M, van der Giet M, Statz M, et al.The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.Circulation,2003,107:992-995.
8Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy.Semin Dial,2002,15:329-337.
9Venugopal SK, Devaraj S, Yuhanna I, et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.Circulation,2002,106:1439-1441.
10Stenvinkel P, Barany P, Heimburger O, et al.Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?Kidney Int Suppl,2002,(80):103-108.
